Documentation of any spinal cord injury diagnosis is sufficient to establish Medicare coverage for sterile catheter kits (A4297 and A4353) starting Jan. 1, according to a new local coverage determinat ...

PRINCETON, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and ...

UroGen Pharma (URGN) announced that the Centers for Medicare and Medicaid Services, CMS, has assigned a permanent Healthcare Common Procedure Coding System, HCPCS, Level II J Code, J9282, for ZUSDURI ...

The Centers for Medicare & Medicaid Services (“CMS”) recently finalized a Medicare payment rule with significant implications for life ...

CMS finalized a rule that fundamentally changes Medicare payment methodology for a broad range of skin substitute products used for wound care. Beginning in January 2026, most skin substitute products ...

ZEVASKYN ® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis ...

Netsmart unveils AlphaCoding, an AI-powered coding solution guided by CMS standards to enhance compliance with Benny, the embedded coding assistant.

Mesoblast shares are up 59.59% over the year, recovering from a 45% crash earlier this year due to tariff impacts, with shares currently trading at $2.32.

Oklahoma residents will see 280 new laws take effect on Nov. 1, impacting everything from driving and alcohol-related offenses to real estate transactions. Here are five new laws you need to know abou ...

UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.